Abstract 2600
Background
Atezo (anti–PD-L1) is approved for platinum-treated mUC and other indications. Here, we evaluated long-term OS and safety data from IMvigor211, a randomised study evaluating atezo monotherapy vs chemo in platinum-treated mUC (Powles Lancet 2018; primary analysis median follow-up: ≈ 17 mo).
Methods
Pts with disease progression during or following platinum-based chemo were assigned 1:1 to atezo 1200 mg or chemo (vinflunine, paclitaxel or docetaxel per investigator) IV q3w. OS (primary endpoint) and safety were evaluated descriptively in this ad hoc analysis.
Results
As of 8 Nov 2018, median follow-up was 34.3 mo. OS HRs were similar to those from the primary analysis. 24- and 30-mo OS rates were higher with atezo vs chemo in the intent-to-treat (ITT) and PD-L1 populations (Table). In ITT pts, OS HRs with atezo vs taxanes and vinflunine were 0.73 (95% CI: 0.59, 0.90) and 0.90 (95% CI: 0.74, 1.09), respectively. Grade 3-4 treatment-related adverse events (AEs) occurred in 22% of atezo-treated pts and 43% of chemo-treated pts (Grade 5 treatment-related AEs in 1% vs 2%, respectively). AEs leading to treatment discontinuation occurred in 9% of atezo-treated pts and 18% of chemo-treated pts. 11% of atezo-treated patients had a Grade 3-4 AE of special interest (vs 2% with chemo). 29% and 31% of pts in the atezo and chemo arms, respectively, received ≥ 1 subsequent non-protocol therapy; 8% in the chemo arm had non-protocol immunotherapy.Table:
918P OS in IMvigor211 ITT and PD-L1 populations
PD-L1 IC2/3 | PD-L1 IC1/2/3 | ITT | ||||
---|---|---|---|---|---|---|
Chemo n = 118 | Atezo n = 116 | Chemo n = 309 | Atezo n = 316 | Chemo n = 464 | Atezo n = 467 | |
Number of deaths (% of randomised pts) | 97 (82) | 85 (73) | 269 (87) | 261 (83) | 403 (87) | 386 (83) |
Median OS (95% CI), mo | 10.6 (8.4, 12.2) | 11.1 (8.6, 15.4) | 8.2 (7.4, 9.5) | 8.9 (8.2, 10.9) | 8.0 (7.2, 8.6) | 8.6 (7.8, 9.6) |
Stratified HR (95% CI) | 0.87 (0.64, 1.17) | 0.84 (0.70, 1.00) | 0.82 (0.71, 0.94) | |||
24-mo OS rate (95% CI) | 19% | 33% | 14% | 22% | 13% | 23% |
(12, 27) | (24, 42) | (10, 17) | (18, 27) | (10, 16) | (19, 26) | |
30-mo OS rate (95% CI) | 17% | 29% | 10% | 18% | 10% | 18% |
(10, 24) | (21, 38) | (7, 14) | (14, 23) | (7, 13) | (15, 22) |
Data cutoff, 8 Nov 2018. Median follow-up, 34.3 mo (range: 0-42.3). Stratification factors: PD-L1 status on tumour-infiltrating immune cells (IC), chemo type, liver metastases, and number of prognostic risk factors. PD-L1 status on IC evaluated per VENTANA SP142 assay.
Conclusions
In this long-term update from IMvigor211, including 24- and 30-mo OS rates, continued OS benefit in favor of atezo vs chemo was observed in the ITT population and in PD-L1 subgroups. No formal statistical comparisons were performed in this ad hoc analysis. Safety results were consistent with those in the primary analysis.
Clinical trial identification
NCT02302807.
Editorial acknowledgement
Jessica Men, PharmD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
M.S. Van der Heijden: Honoraria (institution), Research grant / Funding (institution): Astellas; Honoraria (institution), Research grant / Funding (institution): BMS; Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Honoraria (institution), Travel / Accommodation / Expenses: MSD; Honoraria (institution): Janssen. Y. Loriot: Advisory / Consultancy: Roche. I. Duran: Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: MSD; Advisory / Consultancy: Pharmacyclycs; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Astellas. A. Ravaud: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis. M.M. Retz: Full / Part-time employment: Technical University Munich, Germany. N.J. Vogelzang: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Caris; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Esai; Advisory / Consultancy: Tolero; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Exelixis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Clovis; Travel / Accommodation / Expenses: SWOG; Travel / Accommodation / Expenses: US Oncology. B. Nelson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. J. Wang: Advisory / Consultancy, Full / Part-time employment: Roche/GNE. X. Shen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. T. Powles: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: F. Hoffmann-La Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Travel / Accommodation / Expenses: Exelixis; Honoraria (self), Travel / Accommodation / Expenses: Merck; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Travel / Accommodation / Expenses: Incyte; Honoraria (self), Travel / Accommodation / Expenses: Seattle Genetics.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract